PHILADELPHIA, PA and REHOVOT, ISRAEL, Nov 28, 2011 (MARKETWIRE via COMTEX) –Rosetta Genomics, ltd. /quotes/zigman/102850/quotes/nls/rosg ROSG +3.85% , a leading developer andprovider of microRNA-based molecular diagnostics, announces thatresults from a joint study by researchers at Rosetta Genomics and theDepartment of Cardiovascular Medicine, Lady Davis Carmel MedicalCenter in Haifa, Israel, show that elevated serum levels of specificmicroRNAs identify systolic heart failure (HF) patients and correlatewith important clinical prognostic parameters. The study, titled “Serum Levels of microRNAs in Patients with HeartFailure,” was published online on November 25, 2011, and is set toappear in the December 2011 print edition of the European Journal ofHeart Failure. The complete article can be viewed online at: eurjhf.oxfordjournals.org/cgi/content/full/hfr155? . in this study, researchers characterized the levels of microRNAs inthe sera of chronic systolic HF patients versus controls, andassessed the possible correlation between elevation in the levels ofspecific microRNAs and clinical prognostic parameters in HF patients. The levels of 186 microRNAs were measured in the sera of 30 stablechronic systolic HF patients and 30 controls using qRT-PCR. Thedifferences in microRNA levels between the two groups werecharacterized and a score, based on the levels of four specificmicroRNAs with the most significant increase in the HF group(miR-423-5p, miR-320a, miR-22, and miR-92b), was defined. — The score, based on serum levels of miR-423-5p, miR-320a, miR-22 and miR-92b identified systolic HF patients and showed correlation with important clinical prognostic parameters. — The score was able to discriminate HF patients from controls with sensitivity and specificity of 90%. — in the HF group, there was a significant association between the score and important clinical prognostic parameters; high microRNA scores were correlated with elevated serum brain natriuretic peptide (BNP) levels (p=0.002), wide QRS (p=0.009), increased end diastolic diameter (p=0.03) and increased left atrial diameter (p=0.01). Commenting on the clinical utility for such a potential microRNA asprognostic markers, Offer Amir, M.D., Lady Davis Carmel MedicalCenter & Heart Failure Clinic and the lead author of the study, said,”Diagnosis and risk stratification of patients with HF remain achallenge. The results of this study demonstrated that these fourspecific microRNAs may indeed serve as biomarkers for the diagnosisand risk stratification of HF patients. Early identification ofpatients at higher risk for severe HF could lead to earlierintervention that would potentially improve outcomes. “Previous studies that demonstrated altered levels of microRNAs inthe circulation of cardiac patients, combined with an increasingunderstanding of their role in myocardial injury and remodeling, haveled to an appreciation for the potential use of microRNAs asbiomarkers of myocardial injury and HF. The results of our currentstudy are consistent with this notion, showing that increased levelsof specific microRNAs in the circulation of HF patients may be usedas markers for HF diagnosis. with regard to HF severity, ourunderstanding of the clinical impact of microRNAs in HF patients isstill in its infancy. However, studies showing correlations betweencirculating microRNAs and clinical parameters, similar to thosereported in our work, are beginning to emerge,” added Dr. Amir. “We are especially pleased with these positive data demonstrating theclinical utility of our serum-based microRNA diagnostic to identifyHF patients,” said Kenneth a. Berlin, President and Chief ExecutiveOfficer of Rosetta Genomics. “With nearly 4.4 million patientsdiagnosed with HF in the US, there is a very large market opportunityfor a simple, blood-based, prognostic test for HF especially giventhe complexity, prevalence and expense of treating this disease. Wehave an excellent patent position on this initial microRNA signatureand look forward to continuing to advance the development of thispotentially powerful, blood-based microRNA diagnostic test forstratification of patients with HF and hope to have it ready tolaunch by the end of 2013.” about Heart Failure Heart failure (HF) is a complex clinicalsyndrome that can result from any structural or functional cardiacdisorders that impair the ability of the ventricles to fill with oreject blood. it is the most prevalent disease in the Western worldand is the only cardiovascular disease whose prevalence continues torise. it is estimated that 5 million Americans have HF andapproximately 500,000 new cases are diagnosed each year. in additionto its high prevalence, heart failure is also the most expensivedisease to treat in Western countries. American Heart Associationestimates from 2004 showed that more than $26 billion per year wasspent on treating patients with heart failure. about miRview(R) Products miRview(R) are a series of microRNA-baseddiagnostic products offered by Rosetta Genomics. miRview(R) mets andmiRview(R) mets^2 accurately identify the primary tumor type inprimary and metastatic cancer including Cancer of Unknown Primary(CUP). miRview(R) squamous accurately identifies the squamous subtypeof non-small cell lung cancer, which carries an increased risk ofsevere or fatal internal bleeding and poor response to treatment forcertain therapies. miRview(R) meso diagnoses mesothelioma, a cancerconnected to asbestos exposure. miRview(R) lung accurately identifiesthe four main subtypes of lung cancer using small amounts of tumorcells. miRview(R) tests are designed to provide objective diagnosticdata; it is the treating physician’s responsibility to diagnose andadminister the appropriate treatment. in the U.S. alone, RosettaGenomics estimates that approximately 200,000 patients a year maybenefit from the miRview(R) mets and miRview(R) mets^2 test, 60,000from miRview(R) squamous, 60,000 from miRview(R) meso and more than 1million patients worldwide from miRview lung. The Company’s tests areoffered directly by Rosetta Genomics in the U.S., and throughdistributors around the globe. for more information, please visit mirviewdx.com . Parties interested in ordering the test cancontact Rosetta Genomics at (215) 382-9000 ext. 309. about microRNAs microRNAs (miRNAs) are recently discovered, smallRNAs that act as master regulators of protein synthesis, and havebeen shown to be highly effective biomarkers. The unique advantage ofmicroRNAs as biomarkers lies in their high tissue specificity, andtheir exceptional stability in the most routine preservation methodsfor biopsies, including Formalin Fixed Paraffin Embedded (FFPE) blocktissue and fine needle aspirate (FNA) cell blocks. it has beensuggested that their small size (19 to 21 nucleotides) enables themto remain intact in FFPE blocks, as opposed to messenger RNA (mRNA),which tends to degrade rapidly. in addition, early preclinical datahas shown that by controlling the levels of specific microRNAs,cancer cell growth may be reduced. to learn more about microRNAs,please visit rosettagenomics.com . about Rosetta Genomics Rosetta Genomics develops and commercializesa full range of microRNA-based molecular diagnostics. Founded in2000, the company’s integrative research platform combiningbioinformatics and state-of-the-art laboratory processes has led tothe discovery of hundreds of biologically validated novel humanmicroRNAs. Building on its strong patent position and proprietaryplatform technologies, Rosetta Genomics is working on the applicationof these technologies in the development and commercialization of afull range of microRNA-based diagnostic tools. The Company’s miRviewproduct line is commercially available through its Philadelphia-basedCAP-accredited, CLIA-certified lab. Forward-Looking Statements various statements in this releaseconcerning Rosetta’s future expectations, plans and prospects,including without limitation, statements relating to the potential ofmicroRNAs in the diagnosis and treatment of disease, constituteforward-looking statements for the purposes of the safe harborprovisions under The Private Securities Litigation Reform Act of1995. Actual results may differ materially from those indicated bythese forward-looking statements as a result of various importantfactors, including risks related to: Rosetta’s approach to discovermicroRNA technology and to work on the application of this technologyin the development of novel diagnostics and therapeutic tools, whichmay never lead to commercially accepted products or services;Rosetta’s ability to obtain, maintain and protect its intellectualproperty; Rosetta’s ability to enforce its patents against infringersand to defend its patent portfolio against challenges from thirdparties; Rosetta’s need and ability to obtain additional funding tosupport its business activities; Rosetta’s dependence on thirdparties for development, manufacture, marketing, sales, anddistribution of products; Rosetta’s ability to successfully developits products and services; Rosetta’s ability to obtain regulatoryclearances or approvals that may be required for its products andservices; the ability to obtain coverage and adequate payment fromhealth insurers for the products and services comprising Rosetta’stechnology; competition from others using technology similar toRosetta’s and others developing products for similar uses; Rosetta’sdependence on collaborators; and Rosetta’s short operating history;as well as those risks more fully discussed in the “Risk Factors”section of Rosetta’s Annual Report on Form 20-F for the year endedDecember 31, 2010 as filed with the Securities and ExchangeCommission. in addition, any forward-looking statements representRosetta’s views only as of the date of this release and should not berelied upon as representing its views as of any subsequent date.Rosetta does not assume any obligation to update any forward-lookingstatements unless required by law. Company Contact: Rosetta Genomics Ken Berlin President & CEO (215) 382-9000 ext. 326 investors@rosettagenomics.com Investor Contacts: LHA Anne Marie Fields (212) 838-3777 afields@lhai.com Bruce Voss (310) 691-7100 bvoss@lhai.com SOURCE: Rosetta Genomics, ltd. mailto:investors@rosettagenomics.com mailto:afields@lhai.com mailto:bvoss@lhai.com Copyright 2011 Marketwire, Inc., all rights reserved. Posts Related to Study Showing Potential for microRNAs as Biomarkers for Heart Failure Prognosis Published in European Journal of Heart Failure Study Published in World Journal of Gastroenterology Shows Potential for microRNAs to Predict Gastric Cancer Recurrence PHILADELPHIA and REHOVOT, Israel, Nov. 4, 2011 /PRNewswire via COMTEX/ –Rosetta Genomics, Ltd. /quotes/zigman/102850/quotes/nls/rosg ROSG +6.43% , a leading developer and provider of microRNA-based molecular … Mesothelioma Breath Test for Diagnosis? :: Accident and Injury Lawyer Blog Diagnosis of malignant pleural mesothelioma is difficult and can often be mistaken for pneumonia, leading to a delay in treatment. But there is a new … Trasylol Kidney Damage Side Effects Bayer’s Trasylol problems are growing following increasing reports of the drug’s side effects. Trasylol has recently been linked to a higher risk of kidney damage, … Plexxikon Novel Agents Aim to Address Cancer Treatment in New Ways BERKELEY, Calif., Nov 13, 2011 (BUSINESS WIRE) —-Next Generation BRAF Inhibitors Profiled– Plexxikon Inc., a member of Daiichi Sankyo Group, today announced scientific findings from … Vitamin A- Posible New Drug For Mesothelioma Vitamin A is a very important vitamin to maintaining health. Vitamin A is found in foods like carrots and it is well known for its …
Read More...
